Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Lintuzumab-Ac225 |
Synonyms | |
Therapy Description |
Lintuzumab-Ac225 is an anti-CD33 antibody in conjugation with a radioactive isotope (225Ac) that has anti-leukemia activity (PMID: 24857092). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lintuzumab-Ac225 | HuM195-Ac225|Actimab-A|Actinium Ac 225 Lintuzumab | CD33 Antibody 13 | Lintuzumab-Ac225 is an anti-CD33 antibody in conjugation with a radioactive isotope (225Ac) that has anti-leukemia activity (PMID: 24857092). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02998047 | Phase I | Lintuzumab-Ac225 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Terminated | USA | 0 |